Opportunity Information: Apply for RFA AI 19 024
The U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) is a National Institutes of Health (NIH) discretionary grant opportunity (Funding Opportunity Number RFA-AI-19-024) that supports collaborative biomedical research focused on key infectious disease priorities relevant to both the United States and South Africa. This announcement continues the established U.S.-South Africa collaborative program into a second phase, using the NIH R01 mechanism, with clinical trials permitted but not required ("Clinical Trial Optional"). In practical terms, applicants may propose studies ranging from foundational and translational research through to certain clinical research activities, as long as the proposed work fits within the scope and requirements of the R01 mechanism and the FOA.
The scientific scope centers on infectious diseases and related vector research, with explicit emphasis on tuberculosis, sexually transmitted infections, parasitic infections, arboviruses, and emerging or re-emerging viral pathogens. The opportunity also highlights vector biology and vector control, signaling interest in research that addresses how vectors contribute to transmission dynamics and how interventions might reduce transmission. Taken together, these areas reflect major burdens of disease and outbreak risks, and they also align with research themes where binational collaboration can add value through shared expertise, complementary infrastructure, and access to relevant populations, pathogens, and field settings.
Eligibility is notably restricted on the non-U.S. side. While foreign organizations and foreign institutions are generally listed as eligible, this FOA specifically limits eligibility to non-domestic entities that are National Research Foundations from South Africa (as defined in the announcement). This means not all South African institutions can apply directly under this FOA unless they meet the definition of a qualifying National Research Foundation entity. At the same time, non-domestic (non-U.S.) components of U.S. organizations are explicitly not eligible to apply, which helps clarify that a U.S. institution cannot use an overseas branch office or similar non-U.S. component as the applicant entity. Even with these restrictions, the FOA allows foreign components as defined in the NIH Grants Policy Statement, meaning a U.S. applicant may be able to include a foreign component as part of an overall project structure if it meets NIH policy definitions and the FOA does not otherwise prohibit it.
From an administrative and funding perspective, the award is categorized under CFDA 93.855 (NIH infectious diseases-related assistance), and the posted maximum budget level (award ceiling) is $350,000. The opportunity was created on March 15, 2019, and the original closing date for applications was July 26, 2019. The notice does not specify the exact number of expected awards in the provided source text, but it is clearly structured as a competitive, peer-reviewed NIH grant program.
Overall, this FOA is designed to fund rigorous, collaborative infectious disease research projects that advance biomedical knowledge and public health impact in priority areas such as TB, STIs, parasitic and vector-borne diseases, and emerging viral threats. Its defining features are the continuation of a binational collaboration framework into Phase 2, the use of the R01 mechanism with optional clinical trial involvement, and a tightly defined applicant eligibility pathway for South African participation through qualifying National Research Foundation entities, while still allowing certain foreign components consistent with NIH policy.Apply for RFA AI 19 024
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2019-03-15.
- Applicants must submit their applications by 2019-07-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this grant opportunity?
This opportunity is the "U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases)," an NIH discretionary grant funding opportunity under Funding Opportunity Number (FOA) RFA-AI-19-024. It supports collaborative biomedical research projects that align with infectious disease priorities relevant to both the United States and South Africa.
Which NIH funding mechanism is used?
The program uses the NIH R01 research project grant mechanism. Projects should fit within the scope and requirements of an R01, consistent with the FOA.
Are clinical trials allowed under this FOA?
Yes. The FOA is listed as "Clinical Trial Optional," meaning clinical trials are permitted but not required. Applicants may propose research that includes clinical trial activities, or research that does not involve a clinical trial, as long as the work fits the R01 mechanism and FOA requirements.
What research areas are emphasized?
The scientific scope centers on infectious diseases and related vector research. The FOA explicitly emphasizes tuberculosis, sexually transmitted infections, parasitic infections, arboviruses, and emerging or re-emerging viral pathogens.
Does the FOA support vector-related research?
Yes. The opportunity highlights vector biology and vector control, indicating interest in research addressing how vectors contribute to transmission and how interventions might reduce transmission dynamics.
What types of research approaches can be proposed?
Applicants may propose studies ranging from foundational and translational research through to certain clinical research activities, provided the proposed work fits the scope and requirements of the R01 mechanism and the FOA.
What is the purpose of the U.S.-South Africa collaboration framework in Phase 2?
This announcement continues an established U.S.-South Africa collaborative program into a second phase. The intent is to support rigorous, collaborative infectious disease research that can benefit from binational collaboration through shared expertise, complementary infrastructure, and access to relevant populations, pathogens, and field settings.
Who is eligible to apply from outside the United States?
Eligibility on the non-U.S. side is restricted. While foreign organizations and institutions are generally listed as eligible, this FOA specifically limits eligibility to non-domestic entities that are National Research Foundations from South Africa (as defined in the announcement). This means not all South African institutions can apply directly unless they meet the FOA's definition of a qualifying National Research Foundation entity.
Can a South African university or hospital apply directly?
Based on the provided information, not necessarily. The FOA restricts non-U.S. eligibility to National Research Foundations from South Africa (as defined in the announcement). A South African institution would need to meet that definition to apply as the applicant organization under this FOA.
Are non-domestic components of U.S. organizations eligible to apply?
No. The FOA states that non-domestic (non-U.S.) components of U.S. organizations are not eligible to apply. In practical terms, a U.S. institution cannot submit an application using an overseas branch office or similar non-U.S. component as the applicant entity.
Are foreign components allowed in a project led by a U.S. applicant?
The FOA allows foreign components as defined in the NIH Grants Policy Statement. This suggests a U.S. applicant may be able to include a foreign component within the overall project structure if it meets NIH policy definitions and the FOA does not otherwise prohibit it.
What is the CFDA number associated with this opportunity?
The award is categorized under CFDA 93.855, which corresponds to NIH infectious diseases-related assistance.
What is the maximum budget level (award ceiling) mentioned?
The posted maximum budget level (award ceiling) is $350,000.
When was the opportunity created and when was it due?
The opportunity was created on March 15, 2019. The original closing date for applications was July 26, 2019.
How competitive is this program?
It is described as a competitive, peer-reviewed NIH grant program. The provided information does not specify the exact number of expected awards.
What makes this FOA distinct from other infectious disease funding opportunities?
Key defining features include: (1) a continued binational collaboration framework (Phase 2) between the U.S. and South Africa, (2) use of the R01 mechanism with clinical trials permitted but not required, and (3) tightly defined eligibility for South African participation through qualifying National Research Foundation entities, alongside allowance for certain foreign components consistent with NIH policy.
Browse more opportunities from the same category: Health
Next opportunity: FY2019 Supplemental for Northeast Corridor Grant to the National Railroad Passenger Corporation
Previous opportunity: NCI Awardee Skills Development Consortium: Program Logistics and Evaluation Coordinating Center (U24 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 19 024
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 19 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| Atopic Dermatitis Research Network -Clinical Research Centers (U01 Clinical Trial Optional) Apply for RFA AI 19 015 Funding Number: RFA AI 19 015 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Institutional Translational Research Training Program (T32) Apply for PAR 19 228 Funding Number: PAR 19 228 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Health Services Research Project: Partners Enabling Diagnostic Excellence (R01) Apply for RFA HS 19 003 Funding Number: RFA HS 19 003 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Informatics Methodology and Secondary Analyses for Immunology Data in ImmPort (UH2 Clinical Trial Not Allowed) Apply for PAR 19 229 Funding Number: PAR 19 229 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Preventive Health and Health Services Block Grant– 2019 Apply for CDC RFA OT19 1902 Funding Number: CDC RFA OT19 1902 Agency: Centers for Disease Control - OSTLTS Category: Health Funding Amount: Case Dependent |
| Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed) Apply for RFA AI 19 017 Funding Number: RFA AI 19 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic clinical trial on efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia (U01 Clinical Trial Required) Apply for PA 19 230 Funding Number: PA 19 230 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) Apply for PAR 19 231 Funding Number: PAR 19 231 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| NIH Directors Transformative Research Awards (R01 Clinical Trial Optional) Apply for RFA RM 19 007 Funding Number: RFA RM 19 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors Early Independence Awards (DP5 Clinical Trial Optional) Apply for RFA RM 19 008 Funding Number: RFA RM 19 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Biomarker Discovery and Novel Point-of-Care Diagnostics for Active TB Disease Detection in HIV-1 Infected and Exposed Children (R01 Clinical Trial Optional) Apply for RFA AI 19 036 Funding Number: RFA AI 19 036 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology (P30 - Clinical Trial Not Allowed) Apply for PAR 19 232 Funding Number: PAR 19 232 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Targeted Prevention for Tickborne Diseases (R01 Clinical Trial Not Allowed) Apply for RFA AI 19 037 Funding Number: RFA AI 19 037 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required) Apply for PAR 19 236 Funding Number: PAR 19 236 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required) Apply for PAR 19 235 Funding Number: PAR 19 235 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed) Apply for PAR 19 234 Funding Number: PAR 19 234 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed) Apply for PA 19 237 Funding Number: PA 19 237 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical Trial Not Allowed) Apply for PAR 19 239 Funding Number: PAR 19 239 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed) Apply for PAR 19 240 Funding Number: PAR 19 240 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA HL 20 014 Funding Number: RFA HL 20 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 19 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.